Abstract:Purpose/Objective: (64)Cu-diacetyl-bis(N4-methylthiosemicarbazone) (64Cu-ATSM) is a recently developed PET imaging marker for tumor hypoxia. However, its accuracy, reliability, and sensitivity have not been fully characterized in vivo. Also, activities from intravascular (64) Cu-ATSM that are not related to hypoxia, can also contribute to the PET signal. The purpose of this study is to validate its ability of hypoxia marker in animal mammary tumor model by comparing to immunostaining of a well-known hypoxia marker, EF5, and further characterize the dynamic uptake of 64Cu-ATSM in tumors using compartmental modeling to separate the intravascular signal contribution. Materials/Methods: R3230 mammary adenocarcinoma (R3230Ac) was used as tumor model and was implanted in the flank of Fisher344 rat. A dynamic (64) Cu-ATSM microPET scan was performed with a microPET R4 system. Tumor/muscle ratio and time activity curves were acquired from PET imaging. To validate the spatial correlation between (64) Cu-ATSM uptake and hypoxia area, EF5 and a vascular perfusion marker, Hoechst33342, were also administrated into the same animal during microPET scanning for subsequent histological imaging. Electronic autoradiography was conducted on tumor sections from the same animals. Images from microPET, autoradiography, EF5 immunostaining, Hoechst vascular perfusion, and H&E histology were aligned, and the distribution of (64) Cu-ATSM in the tumor was compared to the EF5/Hoechst fluorescent images. To further characterize the dynamic uptake of (64) Cu-ATSM in the tumor, a two-compartment model was used. In the model, the 64Cu-ATSM concentration is separated into an intravascular concentration (Cp) with vascular volume fraction (Vp) and extravascular concentration (Ce) with effective interstitial volume fraction (Ve). The transfer between the intra- and extra-vascular compartments is described by rate constant k(in) and k(out). After non-linear least square (NLLS) fitting to the dynamic scan data, the overall radioisotope signal in the tumor was separated into intravascular and extravascular components. Vascular volume fraction Vp and rate constant k were also obtained from the fitting. Results: The tumor-muscle ratio (T/M) of (64) Cu-ATSM measured by microPET in R3230Ac was 2.23 ± 0.11, indicating higher uptake in the tumor. The comparison between autoradiography and EF5/Hoechst staining showed high correlations between (64) Cu-ATSM uptake and hypoxia area (image correlation coefficient = 0.76). The area fraction of (64) Cu-ATSM uptake closely followed the area fraction of EF5 staining (0.24 ± 0.04 vs. 0.21 ± 0.03). The (64) Cu-ATSM uptake curves from PET imaging were fitted well by a two-compartment model for the R3230Ac tumor. The time courses of the intravascular and extravascular (64) Cu-ATSM signals were obtained from the NLLS fitting. Vascular volume fraction (Vp) and transfer constant (kin) were (2.50 ± 0.15) % and 0.045 ± 0.001 1/min, respectively. Conclusions: The distribution of (64) Cu-ATSM is closely correlated to tumor hypoxia in R3230Ac tumor. The uptake of (64)Cu-ATSM in R3230Ac can be also characterized by a compartmental model, which can effectively remove the intravascular radioisotope signal from the overall tissue signals, reflecting more accurately the tissue uptake and tumor hypoxia. The calculated tumor vascular volume fraction and transfer rate constant can be used to characterize the change of tumor hypoxia in the future study.

Biodistribution of PET radiotracers in tumor-bearing TRAMP mice administered by retroorbital or jugular vein injections

Ex-vivo biodistribution and micro-PET/CT imaging of 18F-FDG, 18F-FLT, 18F-FMISO, and 18F-AlF-NOTA-PRGD2 in a prostate tumor-bearing nude mouse model.

Performance of nanoScan PET/CT and PET/MR for quantitative imaging of 18F and 89Zr as compared with ex vivo biodistribution in tumor-bearing mice

Preliminary Clinical Application of RGD-Containing Peptides as PET Radiotracers for Imaging Tumors

Development of a new positron emission tomography tracer for targeting tumor angiogenesis: synthesis, small animal imaging, and radiation dosimetry

Biodistribution and Radiation Dosimetry of Multiple Tracers on Total-Body Positron Emission Tomography/computed Tomography.

Biometabolic Distribution of 99Mtc-3Prgd2 and Its Potential Value in Monitoring Chemotherapeutic Effects

Biodistribution in Healthy KM Mice and Micro PET/CT Imaging in U87MG Tumor-Bearing Nude Mice of a New 18F-Labeled Cyclic RGD Dimer

A Novel Tc-99m-Labeled Molecular Probe For Tumor Angiogenesis Imaging In Hepatoma Xenografts Model: A Pilot Study

18F-Alfatide II and 18F-FDG Dual-Tracer Dynamic PET for Parametric, Early Prediction of Tumor Response to Therapy

Quantitative, preclinical PET of translocator protein expression in glioma using 18F-N-fluoroacetyl-N-(2,5-dimethoxybenzyl)-2-phenoxyaniline

(64) Cu-Atsm Micropet Imaging Of Tumor Hypoxia In Mammary Tumor Model: Compartmental Modeling And Immunohistochemistry Analysis

Noninvasive Molecular Imaging of Radioactive Tracers Using Optical Imaging Techniques

Use of a clinical PET/CT scanner for whole body biodistribution of intranasal nanoparticles

Quantitative Analysis and Parametric Mapping of [18F]alf-Nota-prgd2, [18f]fpprgd2 and [68Ga]ga-Nota-prgd2 Using Graphical Method

18F-HX4/18F-FMISO-based micro PET for imaging of tumor hypoxia and radiotherapy-associated changes in mice

Machine Learning-Based Noninvasive Quantification of Single-Imaging Session Dual-Tracer 18F-FDG and 68Ga-Dotatate Dynamic PET-CT in Oncology

Tumor Imaging Using a Standardized Radiolabeled Adapter Protein Docked to Vascular Endothelial Growth Factor.

MicroPET imaging of tumor angiogenesis and monitoring on antiangiogenic therapy with an 18F labeled RGD-based probe in SKOV-3 xenograft-bearing mice

In Vitro and in Vivo Comparative Study of 68Ga-Labeled DOTA-, NOTA-, and HBEDCC-chelated Radiotracers Targeting Prostate-Specific Membrane Antigen

Mapping the Target Localization and Biodistribution of Non-Radiolabeled VMAT2 Ligands in rat Brain